These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15117866)

  • 1. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?
    Beranek JT
    Circulation; 2004 Apr; 109(16):e195-6; author reply e195-6. PubMed ID: 15117866
    [No Abstract]   [Full Text] [Related]  

  • 2. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
    Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
    Mahaffey KW; Granger CB; Nicolau JC; Ruzyllo W; Weaver WD; Theroux P; Hochman JS; Filloon TG; Mojcik CF; Todaro TG; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1176-83. PubMed ID: 12925455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
    Fleisig AJ; Verrier ED
    Expert Opin Biol Ther; 2005 Jun; 5(6):833-9. PubMed ID: 15952913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction.
    Eikelboom JW; O'Donnell M
    JAMA; 2007 Jan; 297(1):91-2. PubMed ID: 17200480
    [No Abstract]   [Full Text] [Related]  

  • 7. Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions.
    Lin GM
    Cardiovasc Hematol Disord Drug Targets; 2011; 11(2):97-101. PubMed ID: 22044037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.
    Patel JA; Ghatak SB
    Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):145-52. PubMed ID: 18537766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
    ; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
    JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors.
    Lin GM; Chu KM; Han CL
    Int J Cardiol; 2011 Jan; 146(2):280-2. PubMed ID: 21109318
    [No Abstract]   [Full Text] [Related]  

  • 11. Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear.
    Gibson CM; Pride YB
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):61-3. PubMed ID: 20129532
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Hudson MP; Armstrong PW; O'Neil WW; Stebbins AL; Weaver WD; Widimsky P; Aylward PE; Ruzyllo W; Holmes D; Mahaffey KW; Granger CB
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):183-92. PubMed ID: 21304097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cardiac cell injury during acute myocardial infarction: possible role for complement inhibition.
    de Zwaan C; van Dieijen-Visser MP; Hermens WT
    Am J Cardiovasc Drugs; 2003; 3(4):245-51. PubMed ID: 14728077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Lin GM; Li YH; Jaiteh LE; Han CL
    Am Heart J; 2012 Dec; 164(6):e19; author reply e21. PubMed ID: 23194495
    [No Abstract]   [Full Text] [Related]  

  • 15. Pexelizumab and the APEX AMI trial.
    Armstrong PW; Granger CB
    JAMA; 2007 May; 297(17):1881; author reply 1881-2. PubMed ID: 17473297
    [No Abstract]   [Full Text] [Related]  

  • 16. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Martel C; Granger CB; Ghitescu M; Stebbins A; Fortier A; Armstrong PW; Bonnefoy A; Theroux P
    Am Heart J; 2012 Jul; 164(1):43-51. PubMed ID: 22795281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
    Théroux P; Armstrong PW; Mahaffey KW; Hochman JS; Malloy KJ; Rollins S; Nicolau JC; Lavoie J; Luong TM; Burchenal J; Granger CB
    Eur Heart J; 2005 Oct; 26(19):1964-70. PubMed ID: 15872036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
    JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
    Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; Malloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH;
    JAMA; 2004 May; 291(19):2319-27. PubMed ID: 15150203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.